A modest average difference
RECONNECT compared bremelanotide with a placebo, a dummy injection, in women before menopause who had HSDD, or distressing low sexual desire.
Across the trials, 1,267 women were assigned by chance to treatment groups for a 24-week comparison.
The study scored women’s answers about desire and distress. The extra average benefit was modest: desire rose by 0.35 points and distress fell by 0.33 points compared with the dummy injection.
The desire scale runs from 1.2 to 6, while the distress measure runs from 0 to 4.
Desire: 0.35 points higher.
The desire scale runs from 1.2 to 6.
Distress: 0.33 points lower.
The distress scale runs from 0 to 4.
These are modest extra changes in group averages, not the total improvement in the medicine group or the share of people helped.
Desire scores and event counts are different
The trials did not establish that bremelanotide led to more satisfying sexual events than the dummy injection. Chance could explain the small differences in those counts.
That result does not mean that nobody benefited. It means that the event-count measure did not establish an added benefit, even though the desire and distress scores differed.
It helps to ask which result a claim is using. “More desire” and “more satisfying events” can sound alike in a headline. They were different measures in this research. A description that gives only the favorable measure leaves out a useful part of the picture.
Who stayed in the research matters
Early departures were uneven: 40% with Vyleesi versus 13% with placebo in the first trial, and 39% versus 25% in the other.
Those figures count departures for every reason, rather than only departures caused by side effects.
An extension follows volunteers from the original trials for longer. This follow-up study enrolled 684 women; 272 completed it.
There was no placebo group in the extension, and everyone knew they were receiving the medicine.
That design can describe what happened among those studied, but it cannot establish a lasting advantage over placebo.
These limits matter when a short account describes results as lasting. Ask who remained, what was compared and whether the account concerns the original trial or the later extension.
How far the answer travels
The main trials were industry-funded, involved mostly White participants and had an average age of 39.
The findings do not certify an untested compounded preparation with the same ingredient name.
Earlier research in men used a nasal form, which was different from the approved injection.
A frequently cited study in men also has a journal expression of concern, a formal notice that raises doubt about the report.
That notice is not described here as a retraction or a proven finding of wrongdoing.